1Gahrton G, Bjorkstrand B. Progress in haematopoietic stem cell transplantation for mutiple myeloma. J Intern Med, 2000, 248:185-201.
2Bensinger W I, Buckner C D, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma., an analysis of risk factors on outcome. Blood, 1996, 88:2787-2793.
3Bensinger W I, Buckner C D, Gahrton G. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am, 1997, 11:147-157.
4Majolino I, Corradini P, Scime R, et al. Allogeneic transplantation of unmanipulated peripheral blood setm cell in patients with multiple myeloma. Bone Marrow Transplant, 1998, 22:449-455.
5Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Pathol Biol, 1999, 47:188- 191.
6Margolis J, Borrello I, Flinn I W. New approaches to treating malignances with stem cell transplantation. Serain Oncol, 2000, 27:524-530.
7Lokhorst H M, Schattenberg A, Cornelissen J J, et al.Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol, 2000, 18:3031-3037.
8Orsini E, Alyea E P, Schlossman R, et al. Changes in Tcell receptor repertoire associated with graft-versustumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant, 2000, 25: 623-632.
9Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998,91:756-763.
10Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood,2001, 97:2574-2579.
